Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbreviated)

NCT00090311 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00090311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00090311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbreviated)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2004
Completion date
July 31, 2006
Enrollment
220 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder